Delivery Order SPE2DR25D3304-SPE2DR26F47S2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 20, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, valued at $1,526.88. This non-set-aside, firm fixed-price delivery order is scheduled for completion by November 21, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in 150 mL quantities, with a contract ceiling value of $2,802.86. This is a firm fixed-price delivery order with an ultimate completion date of November 18, 2025, with no set-aside designation applied. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania—the location of performance for this contract—is a major pharmaceutical...
- The Defense Logistics Agency awarded a $6,392.32 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on December 10, 2025, with completion scheduled for December 11, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under open competition. The product will be performed from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 16, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) with a ceiling value of $2,079.82. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 17, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml oral suspension (180ml) on December 2, 2025, with a ceiling value of $1,208.98. This firm fixed-price delivery order is scheduled for completion by December 3, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award is non-set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a $2,491.42 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL) on November 10, 2025, with an ultimate completion date of November 12, 2025. This firm fixed price delivery order represents a non-competitive set-aside award and will be performed at the contractor's location in Conshohocken, Pennsylvania. The order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $1,218.48 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 180 ml quantities, with performance completion scheduled for November 4, 2025. This non-set-aside award was competitively procured and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, with a ceiling value of $1,809.72. This is a firm fixed-price delivery order with an ultimate completion date of October 24, 2025, and represents a non-set-aside competitive award. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania location, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,721.55 for Quillivant XR 25 mg/5 ml suspension (150 ml) with a firm fixed price structure. The award was made on December 5, 2025, with an ultimate completion date of December 8, 2025. This non-set-aside contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its headquarters as a major pharmaceutical distributor serving...
- SPE2DR25D3304Indefinite Delivery Contract
- SPE2DR25D3304-SPE2DR26F47S2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL) with a ceiling value of $2,328.26 on December 1, 2025, with ultimate completion scheduled for December 2, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger indefinite delivery contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, holds a significant position in the federal medical procurement landscape, particularly for military and veteran healthcare systems. This delivery order for Quillivant XR—an extended-release liquid suspension medication commonly used to treat attention deficit hyperactivity disorder—represents a routine procurement under the company's broad-based pharmaceutical prime vendor contract with the Defense Logistics Agency. The parent indefinite delivery contract enables AmerisourceBergen to supply a wide range of pharmaceutical products, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs globally, including customers such as the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 11/30/25 |